



**Universiteit  
Leiden**  
The Netherlands

## **The battle against antimicrobial resistant bacterial infections: next stage development of antimicrobial peptides**

Gent, M.E. van

### **Citation**

Gent, M. E. van. (2023, May 30). *The battle against antimicrobial resistant bacterial infections: next stage development of antimicrobial peptides.*

Retrieved from <https://hdl.handle.net/1887/3619323>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3619323>

**Note:** To cite this publication please use the final published version (if applicable).


**1**

# **General introduction**

## 1. Major threats for effective treatment of bacterial infections

In 1928, Alexander Fleming revolutionized the (medical) world with the discovery of the antibiotic penicillin [1]. Initially, Fleming's discovery received little attention. In the 1940s however, penicillin could be produced in large quantities due to efforts of Chain and Florey. As a result penicillin entered the military theater at the end of World War II [2]. By the 1950s, a wide variety of antibiotic classes with different modes of action was discovered [3, 4]. These antibiotics became one of the greatest medical advances of the 20th century for the treatment and prevention of bacterial infections, saving millions of lives yearly. Also today, advanced medical care heavily depends on the use of these antibiotics, for example during transplantations and surgery. However, bacteria and other pathogens have evolved in response to the (ab)use of these antibiotics, resulting in the selection of antimicrobial resistant (AMR) strains. Already in 1945, Fleming noted the danger of resistance development during his Nobel lecture: "It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and the same thing has occasionally happened in the body" [5]. Bacteria can acquire resistance to antibiotics through mutation of genes encoding for enzymes, efflux pumps and/or processes altering their cell wall in effect selecting for optimal settings to remove the antibiotic from their system or through genetic exchange mechanisms with other bacteria [6]. AMR is one of the greatest public health threats we face as global community, as it might lead to a scenario where simple infections, such as skin wound infections or bladder infections, can no longer be treated with modern antibiotics. Currently, in the United States and Europe alone about 50,000 deaths annually are caused as a result of AMR and for 2050 it is estimated that this number will increase to 10 million people globally [7]. AMR strains of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae* and *Staphylococcus aureus* among others are increasingly encountered and constitute a major threat to the public health systems [8]. Moreover, biofilm and/or persister formation by these pathogens further hampers the efficacy of antibiotics. Approximately 80% of the chronic and recurrent bacterial infections are biofilm-associated [9]. Biofilms protect bacteria from actions of environmental stressors like antibiotics and effectors of the immune system, and are also a breeding unit for resistance development [9, 10]. **Figure 1** provides an overview of the different stages involved in biofilm formation: the biofilm life-cycle. Biofilm formation is initiated after irreversible attachment of planktonic bacterial cells to a surface, which could be human skin or medical devices like catheters or implant materials [11]. After attachment, biofilms develop as (poly) microbial communities embedded in self-produced extracellular matrix composed of polysaccharides, protein and DNA, that protects the bacteria from hostile factors [12]. Within deeper layers of the biofilm, bacterial cells might change to a metabolically inactive state, so called persister cells [13]. These persister cells are more resistant

to antibiotics that have bacterial targets involved in metabolism, while also actively removing antibiotics from their system via efflux pumps [14]. Additionally, bacteria can hide inside host cells to prevent removal by the immune system and/or antibiotics [15]. The increasing failure of antibiotics and the lack of new antibiotic development with a mode of action different from current antibiotics, highlights the need for novel therapeutic agents.




**Figure 1. The biofilm life-cycle describes the steps involved in bacterial biofilm formation.** Free floating planktonic bacteria (1) bind irreversibly to a surface, e.g. human skin or medical devices (2). These bacteria start to form (poly)microbial communities and produce extracellular polymeric substances (EPS) that forms the biofilm matrix around the bacteria (3). As the biofilm develops and matures, some bacteria residing deeper inside the biofilm might change to a metabolically inactive state, so called persister cells (4). Over time, bacteria can disperse out of the biofilm, revert to a planktonic state and start to colonize new surfaces (5). ● represent *Staphylococcus* bacteria, ■ polymicrobial bacteria and ■ persister cells. Figure is based on Sahli et al. [16].

## 2. Antimicrobial (host defense) peptides

Antimicrobial peptides (AMPs) are considered promising alternatives to antibiotics. AMPs are a class of small peptides that span 10-60 amino acids and are part of the innate immune response in a great variety of organisms, including humans [17]. These peptides exhibit a wide range of biological activities, which include antibacterial, antibiofilm, antiviral, antifungal, anticancer, wound healing and immunomodulatory activities [18]. Until today >3000 AMPs have been identified;

an online database reporting potent AMPs originating from natural sources can be consulted at <https://aps.unmc.edu/>. Since AMPs are a diverse group of peptides, they can be classified based on i) source, ii) activity, iii) structure and iv) amino acid-rich species [19]. The best studied structural classes of human AMPs are cathelicidins and defensins [20]. Two most common characteristics of these AMPs include a predominant cationic charge at physiological pH and  $\geq 30\%$  hydrophobic residues [21, 22]. The cationic charge of these peptides drives the initial electrostatic interaction with the polyanionic outer surface of bacterial cells, i.e. lipopolysaccharide or wall-associated teichoic acids for Gram-negative or Gram-positive bacteria, respectively [22]. AMPs are typically unstructured in aqueous solution, but in presence of a



**Figure 2. Overview of the antimicrobial and immunomodulatory activities of AMPs/HDPs.** Direct antimicrobial activities include antifungal, antibacterial and antiviral activities. The variety of immunomodulatory activities range from effects on cells of the innate and adaptive immunity, but also comprise effects on tumors and wound environment.

biological membrane, these peptides fold into an 'active' amphipathic secondary structure, where hydrophobic residues are oriented opposite from cationic or polar residues [21, 23]. Although the mechanism of action of AMPs is diverse, generally direct interactions with and disruption of the bacterial membrane play a key role. Multiple destabilization models have been proposed to describe these interactions [21]. In addition, AMPs can induce bacterial cell death by acting on intercellular targets after cellular internalization, which can affect DNA/RNA synthesis, protein synthesis or protein folding [24]. Importantly, the risk of resistance development by bacteria in response to AMPs is considered low due to their unspecific and sometimes multifaceted mode of action [17, 25]. It was long thought that direct antimicrobial activities were the primary function of natural AMPs, however, recently this consensus has changed, and immunomodulatory properties are now considered the primary role of natural AMPs [26, 27], hence their alternative name host defense peptides (HDPs). The immunomodulatory properties of HDPs are diverse and include i) chemotaxis of leukocytes, ii) alteration of macrophage and dendritic cell differentiation, iii) modulation of cytokine or chemokine expression [26-29]. Moreover, several HDPs have shown to stimulate angiogenesis and promote wound healing [30, 31]. An overview of the direct antimicrobial and immunomodulatory activities of AMPs/HDPs is described in **Figure 2**.

### **3. Development of synthetic antimicrobial and antibiofilm peptide (SAAP)-148**

Development of novel antimicrobial peptides has been guided primarily by rational design principles, and is increasingly combined with computer-aided methods like artificial intelligence for better structure-activity relationship predictions [32]. The only family member of human cathelicidins is LL-37, which has moderate broad-spectrum antimicrobial activities [33, 34], and is well-known for its immunomodulatory activities [29, 35-37]. LL-37 has served as starting point for development of AMPs with improved bactericidal and antibiofilm activities. First, a library of LL-37 derivatives, where the core antimicrobial region was maintained, was synthesized and hit compound OP-145 (also named P60.4Ac) showed to have improved antimicrobial activities compared to LL-37 [38]. OP-145 was also effective in prevention of *S. aureus* implant-associated infection in rabbits when incorporated in a biodegradable implant coating [39] or *S. aureus* infections on human epidermal models when incorporated in a hypromellose gel [40]. Moreover, OP-145 successfully cured chronic otitis media in 47% of the cases in a phase II clinical trial [41]. Despite these successes, antimicrobial activity of OP-145 was shown to be reduced in presence of biological fluids, like human plasma, wound fluid or urine [38]. Therefore, in an attempt to further improve antimicrobial and antibiofilm activities under these physiological conditions, a second library of LL-37 derivatives was synthesized, which resulted in lead peptide SAAP-148. SAAP-148 is a potent broad-spectrum agent, able to

eradicate multidrug resistant bacteria of the ESKAPE panel (*Enterococcus faecium*, *S. aureus*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa* and *Enterobacter* species) and capable to completely eradicate *S. aureus* and *A. baumannii* biofilm infections from murine skin [42]. Moreover, SAAP-148 can eradicate *S. aureus* persister cells in antibiotic-exposed matured biofilms simulating prosthetic joint infection [43]. SAAP-148 is a membrane disruptive AMP; its mode of action is ascribed to insertion into the bacterial membrane followed by membrane thinning, permeabilization and leakage, resulting in bacterial cell death within minutes [42]. The improved antimicrobial activity of SAAP-148 is a result of superior ability to disrupt the bacterial membrane compared to OP-145 [44]. Importantly, SAAP-148 showed almost no resistance development [42], indicating the therapeutic potential of this AMP for treatment of antimicrobial-resistant bacterial infections.


#### **4. Limitations of antimicrobial peptides and SAAP-148**

Until date, only seven AMPs (including (cyclic) lipo- and/or glycopeptides) have been admitted to the clinic: Gramicidin, Daptomycin, Colistin, Vancomycin, Oritavancin, Dalbavancin and Telavancin [45]. Pharmacokinetic and pharmacodynamic properties related to the peptidic nature of AMPs have hampered their success rate in clinical trials [46]. Challenges for further development of AMPs include i) relatively high hemolytic and cytotoxic activities at antimicrobial concentrations resulting in low selectivity towards bacterial cells over mammalian cells [47-50], ii) limited proteolytic stability due to peptide degradation by proteolytic enzymes produced by the host or bacteria [49-51], iii) limited bioavailability due to binding to plasma and/or serum proteins [51, 52], iv) short systemic half-life [45, 49], v) limited penetration into tissue [51, 53] or bacterial biofilms [54] and vi) expensive production costs especially for long peptide sequences [49-51]. Also SAAP-148 suffers from limitations related to its peptidic nature, such as a small therapeutic window and short half-life due to (plasma) protein binding [55, 56]. Although SAAP-148 has proven successful in treatment of superficial skin wound infections in vivo [42], its antibacterial activities were limited in deeper skin wounds, such as surgical wound infections in rats [55]. Factors contributing to the reduced activity of SAAP-148 in this in vivo surgical wound infection model were related to i) components within the wound micro-environment (e.g. proteins, proteases, etc.), ii) inadequate or relatively slow release from the hydrogel or wound dressing and iii) re-colonization due to relatively high bacterial load in the wounds [55].

#### **5. Strategies to improve antimicrobial peptides**

Several strategies to minimize the peptide-related limitations of SAAPs and AMPs in general can be considered. Such strategies include AMP chemical lead-optimization, combination therapy and innovative peptide delivery systems (**Figure 3**).





**Figure 3.** Three strategies are described that can be used to further improve AMPs like SAAP-148. First, chemical lead-optimization of peptides includes strategies, such as N- or C-terminal capping, incorporation of D-amino acids or changes in length and/or amino acid sequence. Second, AMPs can be combined with agents like antibiotics, AMPs, bacteriophages or other antibacterials that may have synergistic activities. Third, innovative delivery systems are used to encapsulate AMPs and can be applied at the site of infection, where they release their content over time.

### 5.1. Chemical lead-optimization of antimicrobial peptides

Post-translational modifications of natural AMPs are very common and synthetically changing the AMP backbone is one of many strategies that can be investigated in order to improve pharmacokinetic and pharmacodynamic properties of synthetic AMPs. Post-translational modifications occurring in natural AMPs include N-terminal acetylation, C-terminal amidation, incorporation of D-amino acids, disulfide bridge formation and cyclization among others [57]. The most simple synthetic modification is end-capping of AMPs, where N-terminal acetylation greatly improves proteolytic stability of the AMP (sometimes at the cost of antimicrobial activity), while C-terminal amidation generally improves antimicrobial activities of the AMP [58-60]. Moreover, substitution of L-amino acids by D-amino acids, thereby changing chirality of the AMP, is a useful strategy to improve proteolytic stability of AMPs [61-64]. The same holds for retro-inversed AMPs, that have a reversed sequence and thus reversed chirality but where the same amino acid orientation in 3D space is remained [63]. Furthermore, changes in length and/or amino acid sequence of AMPs might also allow for improved properties [64, 65]. Alternatively, AMPs can be conjugated to other molecules to further improve their pharmacokinetic and pharmacodynamic properties. The most extensively studied conjugation method is PEGylation, the process of coupling a polyethylene glycol chain to AMPs. Generally, PEGylation of AMPs results in decreased hemolytic and cytotoxic activities, improved proteolytic stability, reduced binding to serum proteins and improved solubility [66-70]. Nevertheless, reduced antimicrobial activity for PEGylated AMPs is observed,

especially upon conjugation to sufficiently long PEG chains [70, 71]. Conjugation of AMPs to shorter PEG chains allows for similar advantages, while minimizing the loss of antimicrobial activity [72, 73]. In addition, conjugation of AMPs to cell penetrating peptides (CPPs) or penetration enhancers has proven successful for increasing internalization into cells or improved tissue penetration [74, 75]. CPPs are a special group of peptides capable of crossing cellular membranes via endocytosis and/or direct translocation [74, 76, 77]. CPPs often originate from naturally occurring amphiphatic (antimicrobial) peptides, and some examples include penetratin [78], HIV-1 Tat [79] and W/R [80]. Model amphiphilic peptide (MAP) is a special CPP that has additional capabilities as penetration enhancer by modulation of tight junctions [81]. Notably, all beforementioned modifications might allow for improved pharmacokinetic and pharmacodynamic properties of synthetic AMPs. Nevertheless, it is important to carefully review their antimicrobial activities, as these modifications might undesirably decrease antimicrobial activities of the parent peptide.

## **5.2. Combinations of antimicrobial peptides with other therapeutic agents**

Alternatively, antimicrobial activities of AMPs can be enhanced by combining these peptides with other therapeutic agents. Drug combinations can show synergism, additive effect, no interaction or antagonism [82]. Synergy between two drugs occurs when the combined effect of the two drugs is greater than the expected additive effect of these drugs. Synergistic AMP-drug combinations are less likely to induce resistant bacteria [83, 84], and thus have the advantage of further reduction of AMR development. Moreover, these combinations reduce the individual drug dosage and in effect reduce cytotoxic side effects [85]. Reasonably, favorable combinations of AMPs with first-line antibiotics would allow for more effective and shorter therapies compared to current antibiotic regimens. Membrane-disruptive AMPs have been successfully combined with current antibiotics, thereby facilitating antibiotic penetration into the bacterial cytosol allowing the antibiotic to reach its target [86-88]. Likewise, SAAP-148 has shown to synergize with classical antibiotics, such as teicoplanin [89] and demeclocycline [90]. Alternatively, AMPs have also been shown to synergize in combination with a second AMP [85, 91], and addition of a third AMP to the combination further improved these synergistic activities [85]. Moreover, a recent study on bacteriophages showed that these bacterial viruses are able to synergize with AMPs [92]. Finally, other antibacterial agents could also synergize with AMPs, like phage endolysins [93], histones [94] or silver nanoparticles [95]. In the context of bacterial biofilms, AMPs could be combined with agents that inhibit biofilm formation (e.g. inhibitors of quorum sensing [96, 97]) or degrade and/or disaggregate the biofilm matrix (e.g. matrix degrading enzymes [98] and chelating agents [99-102]). Conjugates of AMPs and above mentioned antimicrobials could

also be considered, as conjugates may have several advantages of combined application of two agents [103].

### 5.3. Nano-scaled delivery systems for antimicrobial peptides

Another strategy to improve the therapeutic potential of AMPs is encapsulation of these peptides in drug delivery systems (DDS). Since the introduction of the first controlled-release drug-formulation in the 1950s [104], the field of drug delivery technology has advanced significantly, with nowadays a wide range of DDSs available for the encapsulation of AMPs. These DDSs can be categorized in inorganic materials (e.g. metal-based nanoparticles, mesoporous silica nanoparticles, etc.) and organic materials (e.g. lipid-based nanoparticles, polymeric nanoparticles, polymeric nanogels, etc.) [105]. Nano-scaled DDSs will be the main focus of this thesis, which are usually defined by a particle size ranging from 1 to 100 nm [106], although the same terminology is also used for larger particles up to 500 nm. However, since efficacy and usefulness of DDSs do not only depend on particle size [107], in this thesis nano-scaled DDSs are defined by a particles size ranging from 1 to 500 nm. Several limitations of AMPs can be circumvented by nano-scaled DDSs through i) protection of AMPs from proteolytic enzymes and prevention of binding to plasma and/or serum proteins thus improving the stability and bioavailability of AMPs [108-110], ii) sustained release of AMPs, which reduces the cytotoxicity associated with AMPs [111, 112], iii) assisted transport of AMPs across cellular membranes thus improving intracellular uptake [112, 113], and iv) improved biofilm penetration and intracellular retention [16, 112-114]. Physicochemical properties of these nano-scaled DDSs (e.g. material composition, particle size, surface charge, etc.) affect their pharmacokinetic profile and cellular interaction [115]. Thus, for a certain application one delivery system might be preferred over another. For cutaneous application on skin wounds, nanogels have received great interest as versatile DDS due to their unique properties resulting from the combined features of nanoparticles and hydrogels. These soft nano-scaled particles are formed when water-soluble polymers (natural or synthetic) are cross-linked in three-dimensional space and nanogels have the ability to absorb high amounts of water or biological fluids into the formed network while maintaining their structure [116, 117]. The great amount of hydrophilic groups in the polymeric backbone of nanogels allows for highly efficient AMP encapsulation and provides high biocompatibility [118]. Nanogels are considered as ideal DDSs for skin wound infections as i) their high water content allows for prevention of wound dehydration and creates a moist environment beneficial for wound healing [119, 120], ii) their soft texture and non-adhesive properties allow for patient-friendly application and removal without interfering the wound bed [121], and iii) their porous three-dimensional structure allows for exchange of oxygen that is highly important for the numerous metabolic processes involved in wound healing [122].

## 6. Thesis outline

In this thesis multiple strategies were explored to further develop SAAP-148 to its full potential for treatment of infections caused by antimicrobial resistant bacteria. In **chapter 1** the importance of novel agents and strategies to combat clinical bacterial infections that are hard-to-treat with current antibiotics is emphasized. AMPs, like SAAP-148, are promising alternatives to current antibiotics, however the peptides suffer from some limitations regarding their stability and safety. To circumvent some of these limitations, multiple strategies for optimization of AMPs are being considered, i.e. chemical lead-optimization, combination strategies and (nano)formulation technology. **Chapter 2** describes the antimicrobial, cytotoxic and immunomodulatory activities of a library of SAAP-148 peptides chemically modified with PEG-chains. Next, we hypothesized that the therapeutic potential of SAAP-148 could be enhanced when combined with other antimicrobial agents. **Chapter 3** describes favorable antibacterial activities of SAAP-148 when combined with the novel antibiotic halicin. Furthermore, formulation of SAAP-148 into nanogels could be a promising strategy to reduce the cytotoxicity and thus enhance the selectivity towards bacteria. **Chapter 4** is a comprehensive overview of lipid and polymeric delivery systems thus far investigated for encapsulation of AMPs and AMP coatings for prevention and treatment of bacterial infections. Based on these insights, we encapsulated snake cathelicidin Ab-Cath and SAAP-148 into polymeric nanogels for topical treatment of skin wound infections. These results are described in **chapters 5 and 6**, respectively. Snake cathelicidin Ab-Cath was included in this thesis, because this peptide showed improved antimicrobial activity in presence of human plasma and an improved safety profile compared to SAAP-148. Finally, the main findings of this thesis are summarized and discussed in **chapter 7**. A Dutch summary can be found in the **appendix**.

## References

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *British journal of experimental pathology*. 1929;10(3):226.
2. Ligon BL. Sir Howard Walter Florey--the force behind the development of penicillin. *Semin Pediatr Infect Dis*. 2004;15(2):109-14.
3. McPhillie MJ, Cain RM, Narramore S, Fishwick CW, Simmons KJ. Computational methods to identify new antibacterial targets. *Chem Biol Drug Des*. 2015;85(1):22-9.
4. Zakeri B, Lu TK. Synthetic biology of antimicrobial discovery. *ACS Synth Biol*. 2013;2(7):358-72.
5. Fleming A, Chain E, Florey H. Sir Alexander Fleming-Nobel Lecture: Penicillin. URL <http://www.nobelprize.org/nobelprizes/medicine/laureates/1945/fleming-lecture.html>. 1945.
6. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *Am J Infect Control*. 2006;34(5 Suppl 1):S3-10; discussion S64-73.
7. O'Neill J. Review on antimicrobial resistance. *Antimicrobial resistance: tackling a crisis for the health and wealth of nations*. 2014;2014(4).
8. Cassandra W. The drug-resistant bacteria that pose the greatest health threats. *Nature*. 2017;543:15.
9. Sharma D, Misra L, Khan AU. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrob Resist Infect Control*. 2019;8:76.
10. Lewis K. Multidrug tolerance of biofilms and persister cells. *Curr Top Microbiol Immunol*. 2008;322:107-31.
11. Donlan RM. Biofilm formation: a clinically relevant microbiological process. *Clin Infect Dis*. 2001;33(8):1387-92.
12. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. *Annu Rev Microbiol*. 1995;49:711-45.
13. Sulaiman JE, Lam H. Evolution of Bacterial Tolerance Under Antibiotic Treatment and Its Implications on the Development of Resistance. *Front Microbiol*. 2021;12:617412.
14. Gerdes K, Semsey S. Microbiology: Pumping persisters. *Nature*. 2016;534(7605):41-2.
15. Kamaruzzaman NF, Kendall S, Good L. Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections. *Br J Pharmacol*. 2017;174(14):2225-36.
16. Sahli C, Moya SE, Lomas JS, Gravier-Pelletier C, Briandet R, Hemadi M. Recent advances in nanotechnology for eradicating bacterial biofilm. *Theranostics*. 2022;12(5):2383-405.
17. Zasloff M. Antimicrobial peptides of multicellular organisms. *Nature*. 2002;415(6870):389-95.
18. Haney EF, Mansour SC, Hancock RE. Antimicrobial Peptides: An Introduction. *Methods Mol Biol*. 2017;1548:3-22.
19. Huan Y, Kong Q, Mou H, Yi H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. *Front Microbiol*. 2020;11:582779.
20. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37). *J Leukoc Biol*. 2001;69(5):691-7.
21. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends Biotechnol*. 2011;29(9):464-72.
22. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol*. 2006;24(12):1551-7.
23. Powers JPS, Hancock REW. The relationship between peptide structure and antibacterial activity. *Peptides*. 2003;24(11):1681-91.
24. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. *Expert Rev Anti Infect Ther*. 2007;5(6):951-9.
25. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nat Rev Microbiol*. 2006;4(7):529-36.
26. Hilchie AL, Wuertth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. *Nat Chem Biol*. 2013;9(12):761-8.
27. Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. *Nat Rev Drug Discov*. 2020;19(5):311-32.
28. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small host defense peptides. *Antimicrob Agents Chemother*. 2005;49(5):1727-32.

29. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J Immunol.* 2002;169(7):3883-91.
30. Mangoni ML, McDermott AM, Zasloff M. Antimicrobial peptides and wound healing: biological and therapeutic considerations. *Exp Dermatol.* 2016;25(3):167-73.
31. Nasseri S, Sharifi M. Therapeutic Potential of Antimicrobial Peptides for Wound Healing. *Int J Pept Res Ther.* 2022;28(1).
32. Cardoso MH, Orozco RQ, Rezende SB, Rodrigues G, Oshiro KGN, Candido ES, et al. Computer-Aided Design of Antimicrobial Peptides: Are We Generating Effective Drug Candidates? *Front Microbiol.* 2019;10:3097.
33. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim Biophys Acta.* 2006;1758(9):1408-25.
34. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. *Infect Immun.* 2008;76(9):4176-82.
35. Alexandre-Ramos DS, Silva-Carvalho AE, Lacerda MG, Serejo TRT, Franco OL, Pereira RW, et al. LL-37 treatment on human peripheral blood mononuclear cells modulates immune response and promotes regulatory T-cells generation. *Biomed Pharmacother.* 2018;108:1584-90.
36. Davidson DJ, Currie AJ, Reid GSD, Bowdish DME, MacDonald KL, Ma RC, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. *J Immunol.* 2004;172(2):1146-56.
37. van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ottenhoff THM, van Dissel JT, et al. LL-37 Directs Macrophage Differentiation toward Macrophages with a Proinflammatory Signature. *J Immunol.* 2010;185(3):1442-9.
38. Nell MJ, Tjabringa GS, Wafelman AR, Verrijck R, Hiemstra PS, Drijfhout JW, et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. *Peptides.* 2006;27(4):649-60.
39. de Breij A, Riool M, Kwakman PHS, de Boer L, Cordfunke RA, Drijfhout JW, et al. Prevention of *Staphylococcus aureus* biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145. *J Control Release.* 2016;222:1-8.
40. Haisma EM, Goblyos A, Ravensbergen B, Adriaans AE, Cordfunke RA, Schrupf J, et al. Antimicrobial Peptide P60.4Ac-Containing Creams and Gel for Eradication of Methicillin-Resistant *Staphylococcus aureus* from Cultured Skin and Airway Epithelial Surfaces. *Antimicrob Agents Chemother.* 2016;60(7):4063-72.
41. Peek N, Nell MJ, Brand R, Jansen-Werkhoven T, van Hoogdalem EJ, Verrijck R, et al. Otopical drops containing a novel antibacterial synthetic peptide: Safety and efficacy in adults with chronic suppurative otitis media. *PLoS One.* 2020;15(4):e0231573.
42. de Breij A, Riool M, Cordfunke RA, Malanovic N, de Boer L, Koning RI, et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. *Sci Transl Med.* 2018;10(423).
43. Scheper H, Wubbolts JM, Verhagen JAM, de Visser AW, van der Wal RJP, Visser LG, et al. SAAP-148 Eradicates MRSA Persists Within Mature Biofilm Models Simulating Prosthetic Joint Infection. *Frontiers in Microbiology.* 2021;12.
44. Piller P, Wolinski H, Cordfunke RA, Drijfhout JW, Keller S, Lohner K, et al. Membrane Activity of LL-37 Derived Antimicrobial Peptides against *Enterococcus hirae*: Superiority of SAAP-148 over OP-145. *Biomolecules.* 2022;12(4).
45. Chen CH, Lu TK. Development and Challenges of Antimicrobial Peptides for Therapeutic Applications. *Antibiotics (Basel).* 2020;9(1).
46. Dijksteel GS, Ulrich MMW, Middelkoop E, Boekema BKHL. Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs). *Frontiers in Microbiology.* 2021;12.
47. Bacalum M, Radu M. Cationic Antimicrobial Peptides Cytotoxicity on Mammalian Cells: An Analysis Using Therapeutic Index Integrative Concept. *Int J Pept Res Ther.* 2015;21(1):47-55.
48. Laverty G, Gilmore B. Cationic antimicrobial peptide cytotoxicity. *SOJ Microbiol Infect Dis.* 2014;2(1):1-8.
49. Marr AK, Gooderham WJ, Hancock REW. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. *Curr Opin Pharmacol.* 2006;6(5):468-72.
50. Barreto-Santamaria A, Patarroyo ME, Curtidor H. Designing and optimizing new antimicrobial peptides: all targets are not the same. *Crit Rev Clin Lab Sci.* 2019;56(6):351-73.
51. Vlieghe P, Lisowski V, Martinez J, Khrestchatsky M. Synthetic therapeutic peptides: science and market. *Drug Discov Today.* 2010;15(1-2):40-56.



52. Sivertsen A, Isaksson J, Leiros HKS, Svenson J, Svendsen JS, Brandsdal BO. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. *Bmc Struct Biol.* 2014;14.
53. Ulvatne H. Antimicrobial peptides - Potential use in skin infections. *Am J Clin Dermatol.* 2003;4(9):591-5.
54. Yasir M, Willcox MDP, Dutta D. Action of Antimicrobial Peptides against Bacterial Biofilms. *Materials (Basel).* 2018;11(12).
55. Dijksteel GS, Ulrich MMW, Vlig M, Nibbering PH, Cordfunke RA, Drijfhout JW, et al. Potential factors contributing to the poor antimicrobial efficacy of SAAP-148 in a rat wound infection model. *Ann Clin Microbiol Antimicrob.* 2019;18(1):38.
56. Dijksteel GS, Ulrich MMW, Nibbering PH, Cordfunke RA, Drijfhout JW, Middelkoop E, et al. The functional stability, bioactivity and safety profile of synthetic antimicrobial peptide SAAP-148. *Journal of Microbiology and Antimicrobials.* 2020;12(2):70-80.
57. Wang G. Post-translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering. *Curr Biotechnol.* 2012;1(1):72-9.
58. Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SA, Vogel HJ. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. *PLoS One.* 2010;5(9).
59. Dos Santos Cabrera MP, Arcisio-Miranda M, Broggio Costa ST, Konno K, Ruggiero JR, Procopio J, et al. Study of the mechanism of action of anoplín, a helical antimicrobial decapeptide with ion channel-like activity, and the role of the amidated C-terminus. *J Pept Sci.* 2008;14(6):661-9.
60. Shalev DE, Mor A, Kustanovich I. Structural consequences of carboxyamidation of dermaseptin S3. *Biochemistry.* 2002;41(23):7312-7.
61. Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. *Microbiol Immunol.* 2002;46(11):741-9.
62. Zhao Y, Zhang M, Qiu S, Wang J, Peng J, Zhao P, et al. Antimicrobial activity and stability of the D-amino acid substituted derivatives of antimicrobial peptide polybia-MPI. *AMB Express.* 2016;6(1):122.
63. Kindrachuk J, Scruten E, Attah-Poku S, Bell K, Potter A, Babiuk LA, et al. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. *Biopolymers.* 2011;96(1):14-24.
64. Chen SP, Chen EH, Yang SY, Kuo PS, Jan HM, Yang TC, et al. A Systematic Study of the Stability, Safety, and Efficacy of the de novo Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against *Acinetobacter baumannii*. *Front Microbiol.* 2021;12:678330.
65. Ramesh S, Govender T, Kruger HG, de la Torre BG, Albericio F. Short AntiMicrobial Peptides (SAMPs) as a class of extraordinary promising therapeutic agents. *J Pept Sci.* 2016;22(7):438-51.
66. Guiotto A, Pozzobon M, Canevari M, Manganelli R, Scarin M, Veronese FM. PEGylation of the antimicrobial peptide nisin A: problems and perspectives. *Farmaco.* 2003;58(1):45-50.
67. Imura Y, Nishida M, Matsuzaki K. Action mechanism of PEGylated magainin 2 analogue peptide. *Biochim Biophys Acta.* 2007;1768(10):2578-85.
68. Imura Y, Nishida M, Ogawa Y, Takakura Y, Matsuzaki K. Action mechanism of tachyplesin I and effects of PEGylation. *Biochim Biophys Acta.* 2007;1768(5):1160-9.
69. Kaur N, Dilawari R, Kaur A, Sahni G, Rishi P. Recombinant expression, purification and PEGylation of Paneth cell peptide (cryptdin-2) with value added attributes against *Staphylococcus aureus*. *Sci Rep.* 2020;10(1):12164.
70. Singh S, Papareddy P, Morgelin M, Schmidtchen A, Malmsten M. Effects of PEGylation on membrane and lipopolysaccharide interactions of host defense peptides. *Biomacromolecules.* 2014;15(4):1337-45.
71. Manteghi R, Pallagi E, Olajos G, Csoka I. Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach. *Eur J Pharm Sci.* 2020;144:105197.
72. Cui Q, Xu QJ, Liu L, Guan LL, Jiang XY, Inam M, et al. Preparation, Characterization and Pharmacokinetic Study of N-Terminal PEGylated D-Form Antimicrobial Peptide OM19-8. *J Pharm Sci.* 2021;110(3):1111-9.
73. Morris CJ, Beck K, Fox MA, Ulaeto D, Clark GC, Gumbleton M. Pegylation of Antimicrobial Peptides Maintains the Active Peptide Conformation, Model Membrane Interactions, and Antimicrobial Activity while Improving Lung Tissue Biocompatibility following Airway Delivery. *Antimicrob Agents Ch.* 2012;56(6):3298-308.

74. Guidotti G, Brambilla L, Rossi D. Cell-Penetrating Peptides: From Basic Research to Clinics. *Trends Pharmacol Sci.* 2017;38(4):406-24.
75. Zeiders SM, Chmielewski J. Antibiotic-cell-penetrating peptide conjugates targeting challenging drug-resistant and intracellular pathogenic bacteria. *Chem Biol Drug Des.* 2021;98(5):762-78.
76. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. *J Biol Chem.* 2009;284(49):33957-65.
77. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. *Drug Discov Today.* 2012;17(15-16):850-60.
78. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The 3rd Helix of the Antennapedia Homeodomain Translocates through Biological-Membranes. *Journal of Biological Chemistry.* 1994;269(14):10444-50.
79. Park J, Ryu J, Kim KA, Lee HJ, Bahn JH, Han K, et al. Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. *J Gen Virol.* 2002;83:1173-81.
80. Delaroche D, Ausedat B, Aubry S, Chassaing G, Burlina F, Clodic G, et al. Tracking a new cell-penetrating (W/R) nonapeptide, through an enzyme-stable mass spectrometry reporter tag. *Anal Chem.* 2007;79(5):1932-8.
81. Bocsik A, Grof I, Kiss L, Otvos F, Zsiros O, Daruka L, et al. Dual Action of the PN159/KLAL/MAP Peptide: Increase of Drug Penetration across Caco-2 Intestinal Barrier Model by Modulation of Tight Junctions and Plasma Membrane Permeability. *Pharmaceutics.* 2019;11(2).
82. Doern CD. When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing. *J Clin Microbiol.* 2014;52(12):4124-8.
83. Lewies A, Du Plessis LH, Wentzel JF. Antimicrobial Peptides: the Achilles' Heel of Antibiotic Resistance? *Probiotics Antimicrob Proteins.* 2019;11(2):370-81.
84. Xu XJ, Xu L, Yuan GJ, Wang YM, Qu YQ, Zhou MJ. Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance. *Sci Rep-Uk.* 2018;8.
85. Yu G, Baeder DY, Regoes RR, Rolff J. Combination Effects of Antimicrobial Peptides. *Antimicrob Agents Chemother.* 2016;60(3):1717-24.
86. Pizzolato-Cezar LR, Okuda-Shinagawa NM, Machini MT. Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance. *Front Microbiol.* 2019;10:1703.
87. Grassi L, Masetta G, Esin S, Batoni G. Combination Strategies to Enhance the Efficacy of Antimicrobial Peptides against Bacterial Biofilms. *Front Microbiol.* 2017;8:2409.
88. Ribeiro SM, de la Fuente-Nunez C, Baquir B, Faria-Junior C, Franco OL, Hancock REW. Antibiofilm Peptides Increase the Susceptibility of Carbapenemase-Producing *Klebsiella pneumoniae* Clinical Isolates to beta-Lactam Antibiotics. *Antimicrob Agents Ch.* 2015;59(7):3906-12.
89. Koppen BC, Mulder PPG, de Boer L, Riool M, Drijfhout JW, Zaat SAJ. Synergistic microbicidal effect of cationic antimicrobial peptides and teicoplanin against planktonic and biofilm-encased *Staphylococcus aureus*. *Int J Antimicrob Agents.* 2019;53(2):143-51.
90. Li S, She P, Zhou L, Zeng X, Xu L, Liu Y, et al. High-Throughput Identification of Antibacterials Against *Pseudomonas aeruginosa*. *Front Microbiol.* 2020;11:591426.
91. Yan H, Hancock REW. Synergistic interactions between mammalian antimicrobial defense peptides. *Antimicrob Agents Ch.* 2001;45(5):1558-60.
92. Ludwig T, Hoffmann R, Krizsan A. Construction and Characterization of T7 Bacteriophages Harboring Apidaecin-Derived Sequences. *Curr Issues Mol Biol.* 2022;44(6):2554-68.
93. Gouveia A, Pinto D, Veiga H, Antunes W, Pinho MG, Sao-Jose C. Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins. *Sci Rep-Uk.* 2022;12(1).
94. Doolin T, Amir HM, Duong L, Rosenzweig R, Urban LA, Bosch M, et al. Mammalian histones facilitate antimicrobial synergy by disrupting the bacterial proton gradient and chromosome organization. *Nat Commun.* 2020;11(1):3888.
95. Ruden S, Hilpert K, Berditsch M, Wadhvani P, Ulrich AS. Synergistic Interaction between Silver Nanoparticles and Membrane-Permeabilizing Antimicrobial Peptides. *Antimicrob Agents Ch.* 2009;53(8):3538-40.
96. Balaban N, Gov Y, Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, et al. A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. *Antimicrob Agents Chemother.* 2004;48(7):2544-50.



97. Cirioni O, Mocchegiani F, Cacciatore I, Vecchiet J, Silvestri C, Baldassarre L, et al. Quorum sensing inhibitor FS3-coated vascular graft enhances daptomycin efficacy in a rat model of staphylococcal infection. *Peptides*. 2013;40:77-81.
98. Gawande PV, Leung KP, Madhyastha S. Antibiofilm and antimicrobial efficacy of DispersinB(R)-KSL-W peptide-based wound gel against chronic wound infection associated bacteria. *Curr Microbiol*. 2014;68(5):635-41.
99. Maisetta G, Grassi L, Di Luca M, Bombardelli S, Medici C, Brancatisano FL, et al. Anti-biofilm properties of the antimicrobial peptide temporin 1Tb and its ability, in combination with EDTA, to eradicate *Staphylococcus epidermidis* biofilms on silicone catheters. *Biofouling*. 2016;32(7):787-800.
100. Grassi L, Maisetta G, Maccari G, Esin S, Batoni G. Analogs of the Frog-skin Antimicrobial Peptide Temporin 1Tb Exhibit a Wider Spectrum of Activity and a Stronger Antibiofilm Potential as Compared to the Parental Peptide. *Front Chem*. 2017;5:24.
101. Maisetta G, Grassi L, Esin S, Serra I, Scorciapino MA, Rinaldi AC, et al. The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against *Pseudomonas aeruginosa* in Conditions Mimicking Cystic Fibrosis Sputum. *Int J Mol Sci*. 2017;18(9).
102. Ahire JJ, Dicks LM. Nisin Incorporated With 2,3-Dihydroxybenzoic Acid in Nanofibers Inhibits Biofilm Formation by a Methicillin-Resistant Strain of *Staphylococcus aureus*. *Probiotics Antimicrob Proteins*. 2015;7(1):52-9.
103. Cal PM, Matos MJ, Bernardes GJ. Trends in therapeutic drug conjugates for bacterial diseases: a patent review. *Expert Opin Ther Pat*. 2017;27(2):179-89.
104. Park K. Controlled drug delivery systems: past forward and future back. *J Control Release*. 2014;190:3-8.
105. Jampilek J, Kralova K. Advances in Nanostructures for Antimicrobial Therapy. *Materials (Basel)*. 2022;15(7).
106. Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, et al. Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). *Pure Appl Chem*. 2012;84(2):377-408.
107. Park K. Nanotechnology: What it can do for drug delivery. *J Control Release*. 2007;120(1-2):1-3.
108. Carmona-Ribeiro AM, Araujo PM. Antimicrobial Polymer-Based Assemblies: A Review. *International Journal of Molecular Sciences*. 2021;22(11).
109. Thapa RK, Diep DB, Tonnesen HH. Nanomedicine-based antimicrobial peptide delivery for bacterial infections: recent advances and future prospects. *J Pharm Invest*. 2021;51(4):377-98.
110. Mansson R, Frenning G, Malmsten M. Factors affecting enzymatic degradation of microgel-bound peptides. *Biomacromolecules*. 2013;14(7):2317-25.
111. Klodzinska SN, Pletzer D, Rahanjam N, Rades T, Hancock REW, Nielsen HM. Hyaluronic acid-based nanogels improve in vivo compatibility of the anti-biofilm peptide DJK-5. *Nanomedicine*. 2019;20:102022.
112. Ron-Doitch S, Sawodny B, Kuhbacher A, David MMN, Samanta A, Phopase J, et al. Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV. *J Control Release*. 2016;229:163-71.
113. Menina S, Eisenbeis J, Kamal MAM, Koch M, Bischoff M, Gordon S, et al. Bioinspired Liposomes for Oral Delivery of Colistin to Combat Intracellular Infections by *Salmonella enterica*. *Adv Healthc Mater*. 2019;8(17):e1900564.
114. Faya M, Hazzah HA, Omolo CA, Agrawal N, Maji R, Walvekar P, et al. Novel formulation of antimicrobial peptides enhances antimicrobial activity against methicillin-resistant *Staphylococcus aureus* (MRSA). *Amino Acids*. 2020;52(10):1439-57.
115. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. *Nanomedicine (Lond)*. 2016;11(6):673-92.
116. Gonzalez-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Hydrogels: an interesting strategy for smart drug delivery. *Ther Deliv*. 2013;4(2):157-60.
117. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. *Polymer*. 2008;49(8):1993-2007.
118. Kabanov AV, Vinogradov SV. Nanogels as Pharmaceutical Carriers: Finite Networks of Infinite Capabilities. *Angew Chem Int Edit*. 2009;48(30):5418-29.
119. Pachuau L. Recent developments in novel drug delivery systems for wound healing. *Expert Opin Drug Deliv*. 2015;12(12):1895-909.

120. Eaglstein WH, Davis SC, Mehle AL, Mertz PM. Optimal Use of an Occlusive Dressing to Enhance Healing - Effect of Delayed Application and Early Removal on Wound-Healing. *Arch Dermatol.* 1988;124(3):392-5.
121. Fonder MA, Lazarus GS, Cowan DA, Aronson-Cook B, Kohli AR, Mamelak AJ. Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. *J Am Acad Dermatol.* 2008;58(2):185-206.
122. Haller HL, Sander F, Popp D, Rapp M, Hartmann B, Demircan M, et al. Oxygen, pH, Lactate, and Metabolism-How Old Knowledge and New Insights Might Be Combined for New Wound Treatment. *Medicina-Lithuania.* 2021;57(11).

